By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

Novavax Inc. NVAX shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earnings of 11 ...

There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...

CNN — Novavax on Monday announced the start of the Phase 3 trial of its Covid-19 vaccine in the United States and Mexico. It is the fifth company to launch a large-scale trial of a coronavirus vaccine ...

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts of the ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2. The U.S. Health and ...